What is cagrilintide?
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk. Amylin is a hormone released alongside insulin that plays a role in satiety signaling — cagrilintide's long-acting design keeps that receptor activated far longer than natural amylin does, which is the whole basis for the research interest.
Why it's usually studied alongside semaglutide
Amylin and GLP-1 run on separate receptor systems but both drive appetite regulation — combining them is the entire premise of Novo Nordisk's CagriSema research program, which pairs cagrilintide with semaglutide.
Why people research cagrilintide
Weight-management and metabolic health research account for nearly all the interest here. The specific angle is targeting appetite regulation through two separate hormone systems at once — amylin and GLP-1 — on the premise that this produces a stronger combined effect than working through either pathway alone. It's the same multi-pathway logic behind the other metabolic compounds covered elsewhere on this site.
Cagrilintide isn't carried as a standalone compound yet — but the GLP-1/GIP/glucagon compounds it's usually studied alongside are. Browse the current catalog.
Reading a certificate of analysis (COA)
When sourcing any incretin-pathway research compound, a trustworthy COA states the testing method (HPLC and mass spectrometry), the measured purity percentage, the lot number, and the identity of the testing lab.